2024.12,Crizotinib,Xalkori,Markets and News,API,Crizotinib,877399-52-5

Abstract

Xalkori (crizotinib), developed by Pfizer Inc., marked a breakthrough in targeted therapies for non-small cell lung cancer (NSCLC) harboring ALK and ROS1 rearrangements. Approved initially by the U.S. FDA in 2011, crizotinib catalyzed a paradigm shift in precision oncology, becoming a cornerstone for treating specific genetic profiles in cancer. This paper reviews its scientific development, regulatory journey, market performance, and competitive challenges. While global sales peaked at $524 million annually, the rise of second-generation ALK inhibitors and generic competitors has reshaped its market position. Additional indications, including inflammatory myofibroblastic tumors (IMT), reflect ongoing clinical relevance.

Keywords

Crizotinib, Xalkori, NSCLC, ALK inhibitors, ROS1 inhibitors, targeted therapy, Pfizer, oncology, market competition.

1. Introduction

Crizotinib (Xalkori) represents a targeted therapy for treating cancers driven by abnormal tyrosine kinase signaling. Its primary indications include metastatic ALK-positive and ROS1-positive NSCLC, along with systemic ALK-positive anaplastic large cell lymphoma (ALCL) and refractory inflammatory myofibroblastic tumors (IMT). Since its FDA approval in 2011, crizotinib has shaped the field of molecularly driven cancer treatments. This paper provides a detailed overview of Xalkori, including its approval timeline, market performance, and competitive landscape.

2. Text

2.1 Mechanism of Action

Crizotinib is a multitarget tyrosine kinase inhibitor, primarily inhibiting ALK, ROS1, and c-Met (HGFR). These pathways are crucial in tumor cell proliferation, survival, and metastasis. By targeting these kinases, crizotinib effectively halts tumor progression in malignancies characterized by these genetic aberrations.

2.2 Regulatory Milestones

• FDA Approval: Crizotinib received accelerated FDA approval in August 2011 for ALK-positive NSCLC. A companion diagnostic test for the EML4-ALK fusion was mandatory.
• ROS1-Positive Indication: In March 2016, the FDA expanded its use to include ROS1-positive NSCLC.
• European Approval: The European Medicines Agency (EMA) approved Xalkori in October 2012 for ALK-positive NSCLC.
• China Launch: Entering the Chinese market in July 2018, crizotinib addressed the unmet need for ALK inhibitors in a population with high genetic susceptibility.

2.3 Market Performance

Under the brand name Xalkori, crizotinib delivered $524 million in global sales in 2023. Initial adoption was strong due to its novel mechanism and favorable outcomes in PROFILE clinical trials. However, subsequent ALK inhibitors offering improved central nervous system (CNS) penetration have reduced its market share.

In China, crizotinib gained rapid acceptance post-launch, with inclusion in the National Reimbursement Drug List (NRDL) in 2020 bolstering its accessibility. Despite competition, it remains a significant revenue contributor in emerging markets.

2.4 Competitive Landscape

The advent of second-generation ALK inhibitors has presented significant challenges:

• Alecensa (alectinib): Demonstrates superior CNS efficacy and progression-free survival.
• Zykadia (ceritinib): Offers effectiveness in crizotinib-resistant cases.
• Alunbrig (brigatinib): Targets crizotinib-resistant mutations with extended indications.

Generic crizotinib, produced by manufacturers such as Hansoh Pharma, has drastically reduced treatment costs, intensifying price competition.

2.5 Expanded Indications

Beyond NSCLC, crizotinib is approved for treating ALK-positive systemic ALCL and refractory IMT, showcasing its versatility across oncology indications. Ongoing research into combination therapies aims to overcome resistance mechanisms.

2.6 Recent Developments

Crizotinib's efficacy continues to be explored in combination with immunotherapies and chemotherapy. Emerging studies suggest potential applications in other ALK-driven malignancies, highlighting its sustained clinical relevance despite market competition.

3. Conclusion

Xalkori (crizotinib) remains a landmark in oncology for its pioneering role in molecularly targeted therapy. While competition from second-generation inhibitors and generics has redefined its market dynamics, its contributions to precision medicine endure. Understanding its development, regulatory milestones, and market trajectory provides a window into the challenges and opportunities in the evolving oncology landscape.

Additional Information

Active Pharmaceutical Ingredient

877399-52-5
Crizotinib (Xalkori) (chemical grade, purity ≥99.0%) is currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patent rights are available exclusively for experimental or registration purposes pursuant to national applicable law and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyers are obligated to evaluate the patent situation in their domestic markets and are held liable for uses that do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

Photo Credit: Pexels (pictures are not products, not actual characters, for display only). If there is infringement, we apologize for deletion. If there is any mistake, welcome criticism and correction.

Note: The information or opinions expressed herein are for informational purposes only and do not constitute investment advice to anyone.

References

1. Solomon BJ, Mok T, Kim DW, et al. "First-line crizotinib versus chemotherapy in ALK-positive lung cancer." The New England Journal of Medicine. 2014;371(23):2167-2177.
2. U.S. Food and Drug Administration (FDA). "FDA approves Xalkori for ALK-positive NSCLC." 2011.
3. Pfizer Inc. "Xalkori achieves $524 million in global sales in 2023." Internal report.
4. Chen W, Zheng R, Zeng H, Zhang S. "Epidemiology of lung cancer in China." Thoracic Cancer. 2022;13(4):509-518.
5. National Medical Products Administration (NMPA). "Drug approval details for Xalkori." 2018.
6. Crizotinib Prescribing Information. Updated 2023.